MedTrace Logo

Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

NCT06118788 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-04-17

No results posted yet for this study

Summary

This is a single-arm, single-dose dose-escalation and dose-expansion study.

Conditions

  • Leukemia, Myeloid, Acute

Interventions

BIOLOGICAL

BG1805

A single infusion of BG1805 Injection administered intravenously.

Sponsors & Collaborators

  • Guangzhou Bio-gene Technology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • He Huang, MD · Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-07
Primary Completion
2027-03-31
Completion
2027-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06118788 on ClinicalTrials.gov